The presentation, scheduled for 8:00 am ET, marks a critical update for the company’s precision medicine pipeline. Dabogratinib, a selective FGFR3 inhibitor, represents one of the primary assets generated by Tyra’s proprietary SNÅP platform. Executives will use the session to review findings from the SURF302 study, providing a window into the candidate's clinical potency and tolerability profile.
Tyra Biosciences Sets Date for SURF302 Trial Data Reveal
Investors and oncology researchers will turn their attention to Carlsbad on September 9, 2026, as Tyra Biosciences prepares to disclose initial Phase 2 clinical results for dabogratinib. The company plans to detail the drug's performance in treating intermediate risk non-muscle invasive bladder cancer during an early morning conference call.
Interested parties can access the live webcast and accompanying slide deck through the investor relations portal on the company website. Those intending to join the conversation via telephone must complete a registration process beforehand to receive specific dial-in credentials. Following the event, the company intends to maintain an archived recording of the presentation for a minimum of 90 days, ensuring ongoing access to the data for those unable to attend the live broadcast.
Comments (0)
No comments yet. Be the first!